Cancer Research Technology
Log in Register
Menu

Info

Catalogue Number 153562
Antigen/Gene or Protein Targets Msh3
Parental Line SVG-A immortalized human astrocytes
Synonyms DNA mismatch repair protein Msh3, hMSH3, Divergent upstream protein, DUP, Mismatch repair protein 1, MRP1
Host Human
Tissue Brain
Disease Keywords Neurodegenerative disease such as Huntington’s
Model Knock-Out
Relevance The MSH3 gene encodes a DNA mismatch repair protein important in certain cancer types and in certain neurodegenerative diseases.

Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies.

While ~98% of Msh3 protein is lost in these cells, the abundance of the related proteins Msh2 and Msh6 appear unaffected. This is relevant to DNA mismatch repair.
Production Details Exon 2 of the MSH3 gene was targeted by CRISPR/Cas9. The resulting Msh3-/- cell line encodes a 3 amino acid deletion in Msh3 that results in 98% loss of Msh3 protein, as judged by western blots with two different antibodies.
Conditional No
Research Area Cancer, Cell Cycle, DNA Damage and Repair
Growth/Phenotype Keywords Adherent cell line
Recommended Growing Conditions DMEM supplemented with 10% FBS
Positive Control SVG-A Cell Line, SVG-A Msh3 1.7X Cell Line (derived from Msh3-/- SVG-A Cell Line)
Notes Applications tested:

DNA repair assays
Microsatellite instability
Trinucleotide expansion assay
Cell background for rescue with wild type or variant Msh3 clones
Immunoprecipitation control for Msh2-Msh3 protein complex
Functional analysis of Msh3 variants

CRISPR edited cells.
Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Keogh et al. 2017. Nucleic Acids Res. 45(17):10068-10078. PMID: 28973443.

MutSβ abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions.

Europe PMC ID: 28973443


Add a reference

References: 2 entries

Keogh et al. 2017. Nucleic Acids Res. 45(17):10068-10078. PMID: 28973443.

MutSβ abundance and Msh3 ATP hydrolysis activity are important drivers of CTG•CAG repeat expansions.


Add a reference